NEW YORK (GenomeWeb News) - Agilent Technologies will manufacture siRNAs for Calando, Calando said today.
Agilent will manufacture the active siRNA component for Calando’s targeted siRNA anti-cancer therapeutic, CALAA01. Agilent will also provide Investigational New Drug-enabling services such as pharmacokinetic and toxicity studies and cGMP production.
Calando is a majority owned subsidiary of Arrowhead Research Formed. Founded in 2005, it creates, develops and sells technologies for the therapeutic use of RNAi.
Financial details of the agreement were not disclosed.